Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants ...

Switzerland’s health regulator Swissmedic granted marketing authorisation on Tuesday for Novartis Riamet Baby, also known as ...

Swiss drugs regulator Swissmedic said on Tuesday it is reviewing an application from pharmaceutical company Pfizer for a new dosage recommendation for a COVID-19 booster shot for children.

Swiss drugs regulator Swissmedic said on Thursday it had granted temporary approval to Regkirona, antibody medicine that can be used for the treatment of COVID-19 in adults.

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

Norgine, a leading European specialty pharmaceutical company, announced that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy for the treatment of paediatric patients ...